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Abstract: Calanolides are tetracyclic 4-substituted dipyranocoumarins. Calanolide A, isolated from 20 
the leaves and twigs of Calophyllum lanigerum var. austrocoriaceum (Whitmore) P. F. Stevens, is the 21 
first member of this group of compounds with anti-HIV-1 activity mediated by reverse transcriptase 22 
inhibition. Calanolides are classified pharmacologically as non-nucleoside reverse transcriptase 23 
inhibitors (NNRTI). There are at least 15 naturally occurring calanolides distributed mainly within 24 
the genus Calophyllum, but some of them are also present in the genus Clausena. Besides significant 25 
anti-HIV properties, which have been exploited towards potential development of new NNRTIs for 26 
anti-HIV therapy, calanolides have also been found to possess anticancer, antimicrobial and 27 
antiparasitic potential. This review article provides a comprehensive update on all aspects of 28 
naturally occurring calanolides, including their chemistry, natural occurrence, biosynthesis, 29 
pharmacological and toxicological aspects including mechanism of action and structure activity 30 
relationships, pharmacokinetics, therapeutic potentials and available patents. 31 
Keywords: calanolides; pseudocalanolides; calanolide A; Calophyllum; Calophyllaceae; anti-HIV, 32 
reverse transcriptase; non-nucleoside reverse transcriptase inhibitors (NNRTIs). 33 
 34 
1. Introduction 35 
Calanolides are tetracyclic 4-substituted dipyranocoumarins, and their C-ring contains a gem-36 
dimethyl group (Figure 1), e.g., (+)-calanolide A (1), (-)-calanolide B (costatolide) (14) (Figure 2). The 37 
discovery of calanolides (Table 1) from the leaves and twigs of the tree Calophyllum lanigerum var. 38 
austrocoriaceum (Whitmore) P. F. Stevens, collected from Sarawak, Malaysia in 1987 happened during 39 
one of the largest anti-HIV screening programs conducted by the National Cancer Institute (NCI) 40 
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during 1987-1996. In that program, over 30,000 plant extracts were screened utilizing an in vitro cell-41 
based anti-HIV screen that could determine the degree of HIV-1 replication in treated infected 42 
lymphoblastic cells versus that in treated uninfected control cells [1,2]. Calanolide A (1) (Figure 1), 43 
which can be described as a 11,12-dihydro-2H,6H,10H-dipyrano[2,3-f:2',3'-h]chromen-2-one 44 
substituted by a hydroxyl (-OH) group at C-12, methyl groups at positions 6, 6, 10 and 11 and a propyl 45 
group at C-4 (the 10R,11S,12S stereoisomer), was isolated as the first member of anti-HIV compounds, 46 
calanolides, as a potential novel therapeutic option for the treatment of HIV infections. However, a 47 
subsequent attempt to recollect this plant sample failed and the collection of other specimens of the 48 
same species (not necessarily the same variety), afforded only a negligible amount of calanolide A 49 
(1). In fact, calanolides are among the first plant-based compounds to demonstrate potential anti-50 
HIV-1 activity. Later, an extract of the latex of C. teysmanii showed significant anti-HIV activity in the 51 
screening, but the major active compound was (-)-calanolide B (14, also known as costatolide), 52 
regrettably not calanolide A (1) (Figure 2). The anti-HIV activity of (-)-calanolide B (14) was less 53 
potent than that of calanolide A (1), possibly because of difference in stereochemistry at the chiral 54 
centers. To date calanolides A-F and some of their methyl, acetyl and dihydro derivatives have been 55 
reported mainly from various Calophyllum species (Figure 2; Table 1). Among these, the structures of 56 
calanolides C (6) and D (7), as reported initially by Kashman et al. [1] from C. lanigerum, were revised 57 
and renamed as pseudocalanolides C (8) and D (9) [3] (Figure 2). However, the true calanolides C (6) 58 
and D (7) were later reported from C. brasiliense Cambess. [4-6].  59 
A B
C
D
4
10
11
12
 60 
Figure 1: Rings A, B, C and D, and carbon numbering in (+)-Calanolide A (1) 61 
The first isolation process of calanolides from C. lanigerum var. austrocoriaceum, involved multiple 62 
steps, starting with the extraction of dried fruits and twigs of this plant with a 1:1 mixture of 63 
dichloromethane and methanol, followed by a sequential solvent partitioning process involving 64 
various solvents. The n-hexane and CCl4 fractions emerged as the active fractions [1]. Repeated 65 
vacuum liquid chromatography (VLC) on silica gel, eluting with a mixture of n-hexane and ethyl 66 
acetate afforded crude calanolides, which were further purified by HPLC, employing normal phase 67 
for calanolide A (1), calanolide B (4) and pseudocalanolide D (9) [reported incorrectly as calanolide 68 
D (7)], while reversed-phase for 12-acetoxycalanolide A (2), 12-methoxycalanolide A (3), 12-69 
methoxycalanolide B (5), pseudocalanolide C (8) [reported as calanolide C (6)] and calanolide E (10). 70 
The structures of these compounds were determined by a combination of UV, IR, NMR and MS 71 
spectroscopic methods, and all spectroscopic data were published [1]. The absolute stereochemistry 72 
of calanolides A (1) and B (4) was confirmed by a modified Mosher’s method. 73 
There is a review [7] and a book chapter on calanolides [8], published about six years ago, that 74 
mainly cover anti-HIV activity, and the literature published until early 2014. This present review is 75 
not on the genus Calophyllum, the family Calophyllaceae or pyranocoumarins a such, but it 76 
exclusively focuses on various aspects of naturally occurring calanolides. This review is significantly 77 
different from any other previous articles on calanolides in its approach and coverage, and is a 78 
comprehensive update on naturally occurring calanolides, encompassing their chemistry, natural 79 
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occurrence, biosynthesis, pharmacological and toxicological aspects including mechanism of action 80 
and structure activity relationships, pharmacokinetics, therapeutic potentials and available patents. 81 
 
Calanolide A (1) R = H 
12-O-Acetyl-calanolide A (2) R = Ac 
12-O-Methyl-calanolide A (3) R = Me 
 
Calanolide B (4) R = H 
12-O-Methyl-calanolide B (5) R = Me 
 
 
Calanolide C (6) 
 
Revised to Pseudocalanolide C (8) 
 
Calanolide D (7) 
  
Revised to Pseudocalanolide D (9) 
 
Calanolide E (10) 
 
Calanolide E1 (11) 
Calanolide E2 (12) 
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Figure 2 (Contd.). Naturally occurring calanolides 
 
Calanolide F (13) 
(10-epi-calanolide A) 
 
Costatolide (14) 
[10,11-Di-epi-calanolide A or (-)-calanolide B] 
 
7,8-Dihydrocalanolide A (15) 
 
Dihydrocostatolide (16) 
 
Tomentolide B (17) 
Figure 2 (Continued from the previous page). Naturally occurring calanolides 82 
2. Occurrence 83 
Calanolides, calanolide A (1) being the first member of these 4-substituted pyranocoumarins 84 
isolated from C. lanigerum var. austrocoriaceum, are almost exclusively distributed within the genus 85 
Calophyllum L., which comprises a large group of ca. 200 species of tropical trees distributed in the 86 
Indo-Pacific region, but was also reported from one species (Clausena excavate Brum. f.) of the closely 87 
related genus Clausena [9-12] (Table 1). Calanolide A (1) and other calanolides were subsequently 88 
isolated from other Calophyllum species, e.g., C. brasiliense Cambess. [4,13,14], C. inophyllum L. [6], C. 89 
teysmanii Miq. [2] and C. wallichianum Planch. & Triana [15]. In a chemotaxonomic study on the 90 
Calophyllum species, the presence of calanolides was detected in the extracts of C. inophyllum, C. 91 
lanigerum var. austrocoriaceum, C. mole King, C. nodosum, aff. Pervillei Vesque., C. soulattri Burm. f., C. 92 
tacamahaca Willd. and C. teysmanii [9] (Table 1).  93 
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 94 
Table 1. Naturally occurring calanolides, their sources and properties 95 
 96 
Calanolides Sources Physical 
state 
Mol. formula Mol. weight Optical 
rotation 
[a]D 
UV max 
(MeOH) 
nm 
References 
Calanolide A (1) Calophyllum lanigerum var. 
austrocoriaceum 
Oil C22H26O5 370.44 [a]D +60o (c, 
0.7 in CHCl3) 
228, 284 
and 325 
[1, 9, 11, 71] 
Calophyllum brasiliense [4, 62, 81]  
Calophyllum inophyllum [6, 11] 
Calophyllum teysmannii [82] 
Clausena excavata [10] 
12-O-Acetyl-calanolide A (2)  Calophyllum lanigerum var. 
austrocoriaceum 
Oil C24H28O6 412.48 [a]D +20o (c, 
0.5 in CHCl3) 
228, 284 
and 325 
[1]  
12-O-Methyl-calanolide A (3)  Calophyllum lanigerum var. 
austrocoriaceum 
Oil C23H28O5 384.47 [a]D +32o (c, 
0.8 in CHCl3) 
228, 284 
and 325 
[1]  
Calanolide B (4) Calophyllum lanigerum var. 
austrocoriaceum 
Oil C22H26O5 370.44 [a]D +8o (c, 1.0 
in acetone) 
228, 284 
and 325 
[1]  
Calophyllum brasiliense  [5, 62] 
Calophyllum teysmannii var. 
inophylloide 
[9] 
12-O-Methyl-calanolide B (5) Calophyllum lanigerum var. 
austrocoriaceum 
Oil C23H28O5 384.47 [a]D +34o (c, 
0.5 in CHCl3) 
228, 284 
and 325 
[1]  
Calanolide C (6) Calophyllum brasiliense Oil C22H26O5 370.44 - - [4, 5] 
Calanolide D (7) Calophyllum brasiliense Amorphous 
solid 
C22H24O5 368.42 - - [6] 
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Calanolide E (10) Calophyllum lanigerum var. 
austrocoriaceum 
Amorphous 
powder 
C22H28O6 388.50 [a]D +30o (c, 
0.7 in 
acetone) 
- [1, 9, 16] 
Calophyllum 
membranaceum 
[83] 
 
Calophyllum molle [9] 
Calophyllum polyanthum [84] 
Calophyllum teysmannii var. 
inophylloide  
[16] 
Calophyllum wallichianum [15] 
Calanolide E1 (11) Calophyllum lanigerum var. 
austrocoriaceum 
Amorphous 
powder 
C22H28O6 388.50 - - [9, 16, 9]; 
Calophyllum brasiliense  [9, 14] 
Calophyllum molle [9] 
Calanolide E2 (12) Calophyllum lanigerum var. 
austrocoriaceum 
Amorphous 
powder 
C22H28O6 388.50 - - [9, 16] 
Calophyllum brasiliense 
Cambess. 
[14] 
Calophyllum 
membranaceum 
[83] 
 
Calophyllum molle [9] 
Calophyllum polyanthum [84, 85] 
Calophyllum teysmannii var. 
inophylloide  
[9, 16, 9] 
Calanolide F (13) Calophyllum lanigerum var. 
austrocoriaceum 
Amorphous 
powder 
C22H26O5 370.44 [a]D -51.5 (c, 
0.3 in CHCl3) 
227, 283, 
322 
[9, 16]  
Calophyllum teysmannii var. 
inophylloide  
[9, 16] 
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Costatolide (14) 
[(-)-Calanolide B] 
 
Calophyllum brasiliense Crystals 
(M.p. 181-
183o) 
C22H26O5 370.44 [a]D -19.9 (c, 
0.42 in 
CHCl3) 
228, 284 
and 325 
[4] 
Calophyllum costatum [17]  
Calophyllum inophyllum L. [17] 
Calophyllum teysmannii var. 
inophylloide 
[9, 82, 86] 
7,8-Dihydrocalanolide A (15) Calophyllum lanigerum var. 
austrocoriaceum 
Amorphous 
solid 
C22H28O5 372.46 Negative 
optical 
rotation 
- [86] 
Dihydrocostatolide (16) Calophyllum costatum Amorphous 
solid 
C22H28O5 372.46 - - [28]  
Pseudocalanolide C (8) 
[incorrectly named as 
calanolide C (6)] 
Calophyllum lanigerum var. 
austrocoriaceum 
Amorphous 
solid 
C22H26O5 370.44 [a]D +68o (c, 
0.7 in CHCl3) 
- [1, 9, 87]  
Pseudocalanolide D (9) 
[incorrectly named as 
calanolide D (7)] 
Calophyllum lanigerum var. 
austrocoriaceum 
Amorphous 
solid 
C22H24O5 368.43 [a]D +60o (c, 
0.5 in CHCl3) 
- [1, 87] 
Tomentolide B (17) Calophyllum tomentosa Amorphous 
solid 
(M.p. 158-
160o) 
C22H24O5 368.43 Racemic 
mixture 
- [1, 9, 87] 
97 
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 98 
Bernabe-Antonio et al. [5] reported the production of calanolides in a callus culture of C. 99 
brasiliense, where different concentrations and combinations of plant growth regulators were tested 100 
in leaf and seed explants to establish callus cultures capable of producing calanolides. Higher 101 
calanolides B (4) and C (6) production was observed in calluses from seed explants than those 102 
developed from leaves. In continuation of the search for new natural anti-HIV compounds, and at 103 
the same time to find new botanical sources of calanolides, McKee et al. [16] purified calanolide E2 104 
(12), and calanolide F (13) from the extracts of C. lanigerum var. austrocoriaceum and C. teysmanii var. 105 
inophylloide (King.) P. F. Stevens. Later, costatolide (14), also known as (-)-calanolide B, was reported 106 
as an anti-HIV compound present in C. cerasiferum Vesque and C. inophyllum L. [17]. Calanolides A 107 
(1), and C (6), and costatolide (14) were isolated from the leaves of C. brasiliense, and their anti-HIV 108 
potential was evaluated [4]. 109 
 110 
3. Biosynthesis 111 
Calanolides are biosynthesized from the parent simple coumarin umbelliferone (Schemes 1-3). 112 
The biosynthesis of 7-hydroxycoumarin, also known as umbelliferon in plants starts from the amino 113 
acid L-phenylalanine, and proceeds through the formation of trans-cinnamic acid, p-coumaric acid, 114 
2-hydroxy-p-coumaric acid, 2-glucosyloxy-p-coumaric acid, and 2-glucosyloxy-p-cis-coumaric acid 115 
with the help of various enzymes like cinnamate 4-hydroxylase, 4-coumarate-CoA ligase, 4-116 
coumaroyl 2’-hydroxylase and so on [18]. The biosynthesis of dipetalolactone, a pyranocoumarin, 117 
and subsequent conversion to the 3-propyl-intermediate for calanolides may proceed through two 118 
routes, one through conversion of umbelliferone to osthenol (Scheme 1), and the other via formation 119 
of 5,7-dihdroxycoumarin (Scheme 2). Reactions are generally mediated by p450 monooxygenase and 120 
other non-p450 enzymes [19]. 3-Propyl-intermediate is converted to the precursor compound for 121 
calanolides A-C (1, 4 and 6), utilizing the Wagner-Meerwein rearrangement reaction, and the 122 
precursor compound is believed to be converted to calanolides with the help of p450 monooxygenase 123 
enzyme (Scheme 3). Published studies on the biosynthesis of calanolides are rather limited and only 124 
two publications are available on this topic to date [19, 20]. Therefore, detailed knowledge of specific 125 
enzymes involved in the biosynthesis of calanolides is still in its infancy. 126 
 In a recent study, the influence of soil nutrients, e.g., Ca2+ and K+, on the biosynthesis of 127 
pharmacologically active calanolides in the seedlings of C. brasiliense was studied [20]. It was 128 
observed that the use of K+ deficient modified Hoagland solution (MHS) could induce a 15, 4.2 and 129 
4.3-fold decrease of calanolides B (4), C (6), and apetalic acid concentrations in the leaves of the 130 
seedlings, respectively. On the other hand, Ca2+ deficient MHS could lead to a decrease of 4.3 and 2.4-131 
fold for calanolides B (4) and C (6), respectively. This study demonstrated that, like many other plant 132 
secondary metabolites, the biosynthesis of calanolides, albeit genetically controlled, may also be 133 
affected by environmental conditions, e.g., soil nutrients (minerals).  134 
As genes dictate biosynthesis of secondary metabolites, a study was conducted to identify 135 
candidate genes that regulate to the biosynthesis of calanolides in C. brasiliense [19]. The unigene 136 
dataset constructed in this study could offer an insight for further molecular studies of C. brasiliense, 137 
particularly for characterizing candidate genes responsible for the biosynthesis of angular and linear 138 
pyranocoumarins. The candidate genes, e.g., UN36044, UN28345 and UN34582, identified in the 139 
transcriptome of the leaves, stem and roots of C. brasiliense might be involved in the biosynthesis of 140 
calanolides, which are essentially modified angular pyranocoumarins. Candidate unigenes in the 141 
transcriptome dataset were screened using mainly homology-based BLAST and phylogenetic 142 
analyses. It is worthy of mention that the BLAST programs are widely used for searching protein and 143 
DNA databases for optimizing sequence similarities [21]. For protein comparisons, several 144 
definitional, algorithmic and statistical refinements allow substantial decrease in the execution time 145 
of the BLAST programs and enhancement of their sensitivity to weak similarities. 146 
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Umbelliferone
2'-Hydroxy-dihydrodipetalolactone 5-Hydroxy-6-prenyl-seselin
5-Hydroxy-seselinSeselin
Osthenol
Dipetalolactone
 147 
 148 
Scheme 1. Plausible biosynthetic route to 2’-hydroxy-dihydrodipetalolactone from umbelliferone 149 
via formation of 5-hydroxy-6-prenyl-seselin 150 
Umbelliferone
2'-Hydroxy-dihydrodipetalolactone
Dipetalolactone
5,7-Dihydroxycoumarin
6-Prenyl-5,7-dihydroxycoumarin
Alloxanthoxyletol
8-Prenyl-alloxanthoxyletol  151 
 152 
Scheme 2. Plausible biosynthetic route to 2’-hydroxy-dihydrodipetalolactone from umbelliferone 153 
via formation of 8-prenyl-alloxanthoxyletol 154 
 155 
 156 
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3-Propyl-intermediate
Precursor of calanolides
Calanolide A Calanolide B Calanolide C  157 
 158 
Scheme 3. Plausible biosynthetic route to calanolides A (1), B (4) and C (6) from the intermediate, 159 
2’-hydroxy-dihydrodipetalolactone 160 
 161 
4. Pharmacological properties 162 
 Although well-known for non-nucleoside reverse transcriptase inhibitory activity offering anti-163 
HIV potential, calanolides have also been shown to possess various other pharmacological properties 164 
(Figure 3). The following sub-sections deal with anticancer, anti-HIV, antimycobacterial and 165 
antiparasitic activity of naturally occurring calanolides. As much of the published pharmacological 166 
studies, both in vitro and in vivo including human trials, on naturally occurring calanolides are about 167 
their anti-HIV property, over the years, significant amounts of information have become available on 168 
their mechanism of action, structure-activity-relationships, synergistic and/or additive property and 169 
their potential in anti-HIV combination therapy, which have been discussed adequately under 170 
individual headings within the anti-HIV sub-section. All other pharmacological properties of these 171 
compounds as outlined in different publications still require further investigations to establish their 172 
realistic therapeutic potential. Also, in silico pharmacological activity and toxicity studies on these 173 
pyranocoumarins have just begun to emerge in recent years. 174 
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175 
Figure 3. A pictorial summary of pharmacological properties of naturally occurring calanolides 176 
4.1 Anticancer activity 177 
In the later part of 1980s, as a part of the initiative of the United States National Cancer Institute 178 
(NCI), plant samples from the Malaysian flora were collected for routine screening for potential 179 
cytotoxicity against a collection of cancer cell lines as well as for possible anti-HIV activity. One of 180 
the samples, the leaves and twigs of the tree C. lanigerum var. austrocoriaceum, despite not being active 181 
against any of the cancer cell lines tested, showed inhibitory activity of viral replication when tested 182 
against HIV-1 virus [22, 23]. However, later, calanolide A (1) and calanolide C (6) were shown to 183 
possess antiproliferative or antitumor-promoting property through inhibition of TPA-induced EBV-184 
EA activation in Raji cell lines [13]. The phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA) is 185 
a potent stimulator of differentiation and apoptosis in myeloid leukemia cells. Calanolide A (1) was 186 
found to be more active (IC50 = 290 mol ratio/32 pmol TPA) than its 10,11-cis-isomer, calanolide C (6) 187 
(IC50 = 351 mol ratio/32 pmol TPA). It was inferred that 4-substituted pyranocoumarins like 188 
calanolides might possess potential as cancer chemopreventive agents or antitumor-promoters. A 189 
recent study with the crude ethanolic extract of the leaves of C. inophyllum revealed its potential as a 190 
cytotoxic agent (IC50 120 g/mL) against the breast cancer cell line MCF-7 [24]; it was also found to 191 
possess antiproliferative and apoptotic properties. However, no definitive proof was provided to 192 
establish which of the secondary metabolites biosynthesized by this plant, calanolides being one 193 
major class, were responsible for the putative anticancer activity. Although not calanolides, a few 194 
other 4-substituted coumarins, isolated from C. brasiliense, were tested against human leukemia HL-195 
60 cells with some promising results [25], which might highlight the need for more comprehensive 196 
studies with all major 4-susbtitued coumarins, including calanolides, to find antileukemia lead 197 
compounds for new anticancer drug development. Calanolide A (1), isolated from a chloroform 198 
extract of Clausena excavata, was found to induce toxicity to the cells used in a syncytium assay for 199 
anti-HIV activity [10].  200 
The efficacy of calanolide A (1) in AIDS-associated cancer was evaluated in silico utilizing an 201 
integrated approach combining network-based systems biology, molecular docking and molecular 202 
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dynamics [26]. Molecular targets were screened and only the targets, e.g., HRAS, that are common to 203 
HIV and sarcoma, HIV and lymphoma, and HIV and cervical cancer, were utilized in this study. 204 
Calanolide A (1) was found to form a stable complex with the screened target HRAS, which is a small 205 
G protein in the RAS subfamily of the RAS superfamily of small GTPases, and is considered as a 206 
proto-oncogene; when mutated, this proto-oncogene has the potential to cause normal cells to 207 
become cancerous. 208 
4.2 Anti-HIV activity 209 
Calanolide A (1), an anti-HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), paved the 210 
way for the discovery and synthesis of a series of 4-substituted angular pyranocoumarins with 211 
potential anti-HIV property [1, 27]. NNRTIs are a class of anti-HIV drugs that prevent healthy T-cells 212 
in the body from becoming infected with HIV. Kashman et al. [1] first reported this new class of anti-213 
HIV agents from the tropical rainforest tree, C. lanigerum. Calanolide A (1), 12-acetoxycalanolide A 214 
(2), 12-methoxycalanolide A (3), calanolide B (4), 12-methoxycalanolide B (5), pseudocalanolide C (8), 215 
pseudocalanolide D (9) and calanolide E (10) (Figure 2) were isolated through an anti-HIV bioassay-216 
guided isolation. Calanolides A (1) and B (4) were found to be protective against HIV-1 replication 217 
and cytopathicity with EC50 values of 0.1 µM and 0.4 µM, respectively. However, both compounds 218 
were inactive against HIV-2, which is known as less pathogenic than HIV-1 and mainly found in 219 
West African countries. The other compounds showed a low level of anti-HIV-1 activity. This study 220 
involving purified bacterial recombinant reverse transcriptases established that the calanolides are 221 
indeed HIV-1 specific reverse transcriptase inhibitors. A comparative report on the anti-HIV 222 
potentials of calanolide A (1), costatolide (14) and dihydrocostatolide (16) against a series of HIV 223 
isolates of different cellular phenotypes was published by Buckheit et al. [28], which clearly 224 
demonstrated that calanolide A (1) was the best anti-HIV candidate among the three calanolides 225 
tested.  226 
Two analogs of calanolide A (1), i.e., costatolide (14) and dihydrocostatolide (16), were shown to 227 
possess anti-HIV property similar to that of calanolide A (1) [28] and could be ascribed to the class of 228 
NNRTIs. In fresh human cells, costatolide (14) and dihydrocostatolide (16) could significantly inhibit 229 
the low-passage clinical virus strains, including those representative of the various HIV-1 clade 230 
strains, syncytium-inducing and non-syncytium-inducing isolates, and T-tropic and monocyte-tropic 231 
isolates [28, 29]. In continuation of the search for new natural anti-HIV compounds, McKee et al. [16] 232 
purified calanolide E2 (12), and calanolide F (13) from extracts of C. lanigerum var. austrocoriaceum 233 
and C. teysmanii var. inophylloide (King.) P. F. Stevens, and calanolide E2 (12) emerged as one of the 234 
most active anti-HIV compounds. Later, costatolide (14) was reported as an anti-HIV compounds 235 
present in C. cerasiferum Vesque and C. inophyllum L. [17], while calanolides A (1), and C (6), and 236 
costatolide (14), isolated from the leaves of C. brasiliense, were shown to possess anti-HIV potential 237 
[4]. Comparative anti-HIV activities of some naturally occurring calanolides, e.g., calanolide A (1), 238 
costatolide (14) and dihydrocostatolide (16), against various strains of HIV are available in the article 239 
by Buckheit, et al. [28]. 240 
4.2.1 Activity against drug resistant strains of HIV-1 241 
Interestingly, calanolide A (1) was not only found to be active against standard strains of HIV-242 
1, but it was also active against the resistant strains, eAZT-resistant G-9106 strain of HIV-1 and 243 
pyridinone-resistant A17 strain [1, 30]. The activity against the pyridinone-resistant A17 strain was 244 
of interest as this strain is highly resistant to most of the HIV-1 specific NNRTIs, for example, TIBO, 245 
BI-RG-587 and L693,593. Later, it was established that pyranocoumarin 1 could interact with HIV-1 246 
reverse transcriptase within the previously defined common binding site for nonnucleoside 247 
inhibitors [30]. An assessment of the inhibition patterns of the chimeric reverse transcriptases 248 
containing complementary segments of HIV-1 and HIV-2 reverse transcriptases established that there 249 
was a segment between residues 94 and 157 in HIV-1 reverse transcriptase that was crucial for 250 
inhibition by calanolide A (1) [31]. However, it was assumed that there might be a second segment, 251 
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essential for specifying susceptibility to the drug, between amino acids 225 and 427 in HIV-1 reverse 252 
transcriptase. A couple of years later, it was noted that calanolide A (1) was active against virus 253 
isolates resistant to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine and its derivative, [1-254 
benzyloxymethyl-5-ethyl-6-(alpha-pyridylthio)uracil] [32]. Furthermore, this pyranocoumarin (1) 255 
showed activity against HIV with the two most common NNRTI-related mutations, K103N and 256 
Y181C, and was found to select for a mutation that does not cause cross-resistance with any other 257 
NNRTIs under investigation. It was postulated that substitution at codon Y188H of reverse 258 
transcriptase could be associated with 30-fold resistance to calanolide A (1) in vitro [33]. The 259 
compound is essentially inactive against all strains of the less common HIV type 2. It is necessary to 260 
carry out appropriate in vivo experimentations, either in animal models or in human clinical trials, to 261 
understand the true potential of any putative drug candidate. In vivo anti-HIV activity of (+)-262 
calanolide A (1) was assessed in a hollow fibre mouse model [34], and it was observed that this 263 
compound could suppress virus replication in two unique, but separate physiologic compartments 264 
following oral or parenteral administration.  265 
Calanolides were found to possess an enhanced antiviral activity against one of the most 266 
prevalent NNRTI-resistant viruses that is engendered by the Y181C amino acid change in reverse 267 
transcriptase as well as with reverse transcriptases that possess the Y181C change together with AZT-268 
resistant mutations [28, 29]. Calanolides could also be active against viruses containing Y181C and 269 
K103N dual mutations, which are generally highly resistant to other known non-nucleus reverse 270 
transcriptase inhibitors. Anti-HIV activity of naturally occurring calanolides against drug-resistant 271 
strains of HIV have made these compounds promising structural templates for new anti-HIV drug 272 
development. 273 
4.2.2 Calanolides in anti-HIV-1 combination therapy 274 
 For the treatment of HIV infections, use of combination therapy comprising several anti-HIV 275 
drugs has become a common practice in recent years. The synergistic effects of calanolide A (1), 276 
costatolide (14) and dihydrocostatolide (16) [28] in combination with established anti-HIV drugs, e.g., 277 
azidothymidine (AZT), indinavir, nelfinavir and saquinavir, are available in the literature [28]. 278 
Synergistic effects were observed in both cultured cells and animal models when calanolides were 279 
used in combination with other anti-HIV agents [35]. Both calanolide A (1) and costatolide (14) were 280 
found to be effective in combination therapy for HIV infections [36]; in combination with NNRTIs, 281 
costatolide (14) could only synergistically inhibit HIV type 1 with UC38, whilst calanolide A (1) in 282 
combination with one of the NNRTIs helped this drug to retain activity against virus isolates with 283 
the single Y181C mutation [28, 33, 36, 37].  284 
A combination of (+)-calanolide A (1) and nevirapine (marketed under the trade name viramune 285 
among others for the treatment and prevention HIV-1 infection) was found to possess an additive to 286 
weakly synergistic effect in blocking replication of HIV-1 in an in vitro tissue culture assay [33], 287 
indicating the possibility of using (+)-calanolide A (1) in anti-HIV-1 combination therapy. In an in 288 
vivo study using a hollow fibre mouse model [34], the synergistic potential of (+)- calanolide A (1) in 289 
combination therapy with AZT, a well-known anti-retroviral medication, was further established. A 290 
more comprehensive study on the anti-HIV activity of (+)-calanolide A (1) and its analogs, e.g., 291 
costatolide (14), dihydrocostatolide (16) and (+)-12-oxo-calanoldie A, in combination with other 292 
inhibitors of HIV-1 replication was published about a decade ago [29, 38]. Calanolides were found to 293 
display synergistic antiviral interactions with other nucleoside and non-nucleoside reverse 294 
transcriptase inhibitors and protease inhibitors. In addition, additive interactions were also observed 295 
with calanolides when used with other anti-HIV drugs. It was concluded that the utility of convergent 296 
and divergent combination therapies using reverse transcriptase inhibitors and protease inhibitors in 297 
combination with (+)-calanolide A (1) or one of its analogues could be clinically relevant. Budihas et 298 
al. [39] demonstrated significant synergy between -thujaplicinol and calanolide A (1). 299 
 300 
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4.2.3 Structure-activity-relationships (SAR) 301 
Among the naturally occurring calanolides, calanolide A (1) is one of the most potent anti-HIV 302 
compounds and has been the focus of various studies including the study of its possible mechanism 303 
of action, structural modifications, pharmacokinetics and toxicity [9, 40-43]. The structures of 304 
naturally occurring calanolides mainly differ in their stereochemistry at various chiral centers (C-10, 305 
C-11 and C-12) on the ring D (Figures 1 and 2). McKee et al. [16] reported that calanolide-type 306 
compounds with a 12 hydroxyl group (as in compound 1) generally possess anti-HIV activity. While 307 
calanolide A (1) and costatolide (14) were found to be active, (+)-calanolide C (6) was inactive in the 308 
in vitro anti-HIV assay [4, 17]. The inactivity of (+)-calanolide C (6) despite possessing the 309 
pharmacophoric ring D, as well as a propyl group on C-4, could be due to the -cis orientation of 310 
methyl groups on C-10 and C-11.  311 
Like any other optically active drug molecules, optical activity plays an important role in the 312 
anti-HIV activity of calanolides. It has long been established that (+)-calanolide A (1) and (-)-313 
calanolide B (14) are potent HIV-1 inhibitors, whilst (-)-calanolide A and (+)-calanolide B (4) are 314 
inactive against the virus [44]. It should be mentioned here that (+)-calanolide A (1) is the natural 315 
product, but its enantiomer (-)-calanolide A was prepared from the naturally occurring (-)-costatolide 316 
(14), isolated from C. costatum. Similarly, to establish structure-activity-relationships of calanolides, 317 
several analogs of calanolides have been synthesized to date, and tested in anti-HIV assays [45]. 318 
Although the synthesis of calanolides and the anti-HIV activity of synthetic calanolide analogs are 319 
not within the scope of this review, a few examples are given here in the context of structure-activity-320 
relationships. One of the first attempts in this area was from Galinis et al. [45], where 7,8 olefinic 321 
bonds within (+)-calanolide A (1) and (-)-calanolide B (14) were reduced, and C-12 hydroxyl group in 322 
(-)-calanolide B (14) was modified to investigate variations in anti-HIV activity compared to parent 323 
calanolides. In this study, none of the 14 derivatives was found to possess superior activity to parent 324 
calanolides but revealed some preliminary structure-activity requirements for anti-HIV potencies. 325 
Later, in order to identify the structural features of naturally occurring (+)-calanolide A (1) necessary 326 
for its anti-HIV activity and to prepare synthetic analogues, oxo-derivatives (+)-, (-)- and (±)-12-327 
oxocalanolides, were synthesized and tested in vitro using a biochemical reverse transcriptase 328 
inhibition assay for determining anti-HIV activity with a promising outcome [40]. In a review article 329 
covering various aspects of anti-HIV 4-substitued coumarins with an alkyl or a phenyl group as the 330 
substituent, isolated from the genus Calophyllum, summarized that all trans configurations (10R, 11S, 331 
12 S), as in (+)-calanolide A (1) and (+)-inophyllum B (a 4-phenyl-substituted pyranocoumarin), are 332 
essential for the best anti-HIV activity [46].  333 
Most of the SAR studies involving calanolides for their anti-HIV activities concentrated on the 334 
three chiral centers at C-10, C-11 and C-12 of (+)-calanolide A (1) [47, 48]. As the number of naturally 335 
occurring calanolides are rather limited (calanolides A-F) (Figure 2), the SAR studies were often 336 
carried out with natural calanolides as well as their synthetic analogs. Of the diastereomers, 337 
compounds containing 10,11-trans-methylation and 12-(S)-OH chirality (Figure 2) displayed the most 338 
potent activity with EC50 values in between 0.18 and 2.0 M [47]. It was also observed that either the 339 
enantiomers (12-R-OH) or epimeric alcohols, e.g., calanolide C (6) could not produce any noticeable 340 
anti-HIV effect. It could be concluded that the relative stereochemistry at C-10 and C-11 are essential 341 
structural features for potent anti-HIV activity of calanolides, and at the same time, the S 342 
configuration at C-12 as well as the presence of a heteroatom, e.g., O, at C-12 are necessary for anti-343 
HIV effects.  344 
In order to assess the importance of the presence of 11-methyl functionality on calanolide A for 345 
its anti-HIV activity, the activity of the semi-synthetic racemic mixture of 11-demethyl-calanolide A 346 
was compared with the anti-HIV activity of its parent compound, (±)-calanolide A [49]. The in vitro 347 
HIV-1 reverse transcriptase inhibitory activity of these compounds was determined with the isotope 348 
3H assay, which is a thymidine incorporation assay that often utilizes a strategy wherein a radioactive 349 
nucleoside, 3H-thymidine, is incorporated into new strands of chromosomal DNA during mitotic cell 350 
division; a scintillation beta-counter is used to measure the radioactivity in DNA recovered from the 351 
Molecules 2020, 25, x FOR PEER REVIEW 8 of 25 
 
cells in order to determine the extent of cell division that has occurred in response to a test agent. The 352 
cytotoxicity and inhibition of cytopathic effect of (±)-calanolide A and (±)-11-demethyl-calanolide A 353 
were studied in HIV-1 IIIB infected MT-4 cell cultures by the MTT staining method. Both compounds 354 
inhibited HIV-1 reverse transcriptase in vitro with IC50 value of 3.028 M/L and 3.965 M/L, 355 
respectively, for (±)-11-demethyl-calanolide and (±)-calanolide A. They also inhibited cytopathic 356 
effect in HIV-1 IIIB infected MT-4 cell cultures with IC50 values of 1.081 and 1.297 M/L, respectively. 357 
The outcome form this study indicated that (±)-11-demethyl-calanolide had a slightly more potent 358 
anti-HIV activity than (±)-calanolide A, suggesting the methyl functionality at C-11 in calanolide A 359 
(1) might not be an essential structural feature for anti-HIV activity. With the help of synthetic 360 
analogues a few other structural features that could impact on the anti-HIV activity of calanolides 361 
could be identified. Some of those are summarized below:  362 
i. 11,12 Olefination diminishes activity. 363 
ii. A C-12 hetero atom is essential for the activity. 364 
iii. Relative potencies of C-12 ketone, thiol, azide, amine, and acetylated derivatives suggest 365 
stringent spatial and stereochemical requirements around C-12. 366 
iv. The enantiomers of 12-oxocalanolide A, synthetic intermediates containing one fewer 367 
chiral center, still retain anti-HIV potency in the cytopathic assays. 368 
v. The oxygen substituent can either be in the plane of the aromatic system or possess S 369 
configuration. 370 
vi. Optical activity is important. For example, (+)-12-oxocalanolide A and (±)-12-371 
oxocalanolide A have similar (but not same) anti-HIV activity, but (-)-12-oxocalanolide 372 
A is much less active.  373 
vii. The racemic form, for example, (±)-12-oxocalanolide A, is more active than its pure (+)-374 
enantiomer, (+)-12-oxocalanolide A, which suggests a possible synergistic effect in the 375 
combination of the two enantiomers. 376 
viii. Hydrogenation at C-7 and C-8 of calanolides has little effect on the anti-HIV activity, 377 
e.g., the dihydro derivatives of calanolides A (1) and B (4) possess the same activity as 378 
the parent calanolides. 379 
ix. Modifications at C-4 substituent can affect the anti-HIV activity of calanolides. For 380 
example, a methyl substituent at C-4 (as in cordatolides), instead of a propyl function as 381 
in calanolides reduces the anti-HIV potency.  382 
x. Both the surface area of the substituted group attached on C-10, S-R3, and the distance 383 
between atoms O-13 and X-14 (O, N, S), L, of the calanolide  analogues play important 384 
roles in determining the inhibitory activity of HIV-1 [48]. 385 
 386 
With the advent of various modern computational tools and mathematical models, it is now 387 
possible to study quantitative structure activity relationships (QSAR) in silico, and to predict the 388 
potential of any drug candidates for any therapeutic application [50]. A Caco-2 cell permeability 389 
QSAR model has recently been used to study various HIV-1 reverse transcriptase inhibitors, 390 
including (+)-calanolides A (1) and B (4), both of which showed a high degree of permeability [51]. 391 
This parallel computational screening method incorporated approaches of intestinal absorption 392 
prediction, receptor affinity estimation, inhibitor shape similarity, lipophilicity, and index-based 393 
lipophilic efficiency analyses. Calanolide A (1), among a few other HIV-1 reverse transcriptase 394 
inhibitors, emerged as one of the prioritized hits, as a result of guided prioritization task by the better 395 
binding affinity, crystal ligand similarity, permissible logP value and top lipophilic ligand efficiency 396 
scores. 397 
4.2.4 Mechanism of action 398 
 The evaluation of the activity of (+)-calanolide A (1) against reverse transcriptase and 399 
nonnucleoside reverse transcriptase inhibitor-resistant viruses and enzyme kinetic studies for reverse 400 
transcriptase inhibition suggest that this coumarin possibly interacts with the HIV-1 reverse 401 
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transcriptase in a fashion mechanistically different from other known NNTRIs. The biochemical 402 
mechanism of inhibition of HIV-1 reverse transcriptases by calanolide A (1) was studied using two 403 
primer systems, ribosomal RNA and homopolymeric rA-dT(12-18) [52]. Calanolide A (1) was found 404 
to bind near the active site of the enzyme and interfered with dNTP binding; it inhibited HIV-1 405 
reverse transcriptase in a synergistic fashion with nevirapine, further distinguishing it from the 406 
general class of NNRTIs. It was also observed that at certain concentrations, this compound could 407 
bind HIV-1 reverse transcriptase in a mutually exclusive manner with respect to both the 408 
pyrophosphate analog, phosphonoformic acid and the acyclic nucleoside analogue 1-ethoxymethyl-409 
5-ethyl-6-phenylthio-2-thiouracil. It was concluded that calanolide A (1) could share some binding 410 
domains with both phosphonoformic acid and 1-ethoxymethyl-5-ethyl-6-phenylthio-2-thiouracil. It 411 
might interact with reverse transcriptase near both the pyrophosphate binding site and the active site 412 
of the enzyme. Later, the same group of researchers studied possible mechanism of action of action 413 
of calanolide A (1) against the HIV type 1 including a variety of laboratory strains, with EC50 values 414 
of 0.10-0.17 M [52]. Calanolide (1) could inhibit promonocytotropic and lymphocytotropic isolates 415 
from patients in various stages of HIV disease, and drug-resistant strains, and was found to act early 416 
in the infection process like the known HIV reverse transcriptase inhibitor 2', 3'-dideoxycytidine. It 417 
could selectively inhibit recombinant HIV type 1 reverse transcriptase but not cellular DNA 418 
polymerases or HIV type 2 reverse transcriptase. Auwerx et al. [42] studied the possible role of Thr139 419 
in the HIV-1 reverse transcriptase sensitivity to (+)-calanolide A (1). As T139I reverse transcriptase  420 
proved to be resistant to (+)-calanolide A (1), represents a catalytically efficient enzyme, and requires 421 
only a single transition point mutation (ACA→ATA) in codon 139 could provide some explanation 422 
as to why mutant T139I reverse transcriptase virus strains, but not the other strains containing other 423 
amino acid changes at this position, predominantly emerge in cell cultures under (+)-calanolide A (1) 424 
pressure.  425 
Calanolides are non-nucleoside reverse transcriptase inhibitors and mediate their inhibitory 426 
effect in two different template primer systems: primed ribosomal RNA template, and 427 
homopolymeric poly rA-oligoT12-18 primer. Calanolide A (1) was found to inhibit reverse transcriptase 428 
by involving two binding sites, and the action is because of the bi-bi ordered mechanism of reverse 429 
transcriptase, requiring primer binding prior to polymerization [47]. Calanolide A (1) can bind HIV-430 
1 reverse transcriptase in a mutually exclusive manner with the pyrophosphate analogues 431 
phosphoformic acid or 1-ethoxymethyl-5-ethyl-6-phenylthio-2-thiouracil. This indicates that 432 
calanolide A (1) can interact with reverse transcriptase near the pyrophosphate binding site as well 433 
as the active site. Unlike general non-nucleoside reverse transcriptase inhibitors, calanolide A (1) 434 
appears to be at least partially competitive inhibitor of dNTP binding. Clinical and laboratory 435 
assessment on viral load and CD4 count indicated that antiviral effects of calanolide A (1) appeared 436 
to be dose-dependent and maximized on day 14 or 16. Viral life-cycle studies indicated that calanolide 437 
A (1) could act early in the infection process, similar to the known HIV reverse transcriptase inhibitor 438 
2', 3'-dideoxycytidine. In enzyme inhibition assays, calanolide A (1) could potently and selectively 439 
inhibit recombinant HIV type 1 reverse transcriptase but not cellular DNA polymerases or HIV type 440 
2 reverse transcriptase within the concentration range tested. 441 
4.3 Antimycobacterial activity 442 
 The antibacterial (against Bacillus cereus, B. pumilius, B. subtilis, Escherichia coli, Pseudomonas 443 
aeruginosa, Salmonella typhi, Staphylocossus aureus and Vibrio cholerae) and antifungal (against Alternaria 444 
tenuissima, Aspergillus fumigatus, Aspergillus niger, Candida albicans and Candida tropicalis) properties 445 
of Calophyllum species and their bioactive secondary metabolites, including calanolides, are already 446 
known [6, 15, 53-59]. Kudera et al. (2017) [58] reported in vitro growth inhibitory activity of C. 447 
inophyllum extract against diarrhea-causing microorganisms, e.g., Clostridium difficile infant, 448 
Clostridium perfringens, Enterococcus faecalis, Escherichia coli, Listeria monocytogenes and Salmonella 449 
enterica. The extract was particularly active against C. perfringens and L. monocytogenes (MIC = 128 450 
μg/mL). Later, calanolide E (10) was isolated from C. wallichianum and tested for its anti-Bacillus 451 
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activity against Bacillus cereus, B. megaterium, B. pumilus and B. subtilis [16]. However, calanolide E 452 
(10) was not bactericidal on the tested Bacillus species, and at the tested concentration.  453 
Based on the initial findings on promising antimicrobial properties of calanolides and 454 
Calophyllum extracts, efforts have recently been directed to the study on the effect of these compounds 455 
on the acid-fast bacillus Mycobacterium tuberculosis that causes tuberculosis [60-62]. As over the years 456 
several antibiotic resistant and multidrug-resistant M. tuberculosis strains have emerged, and 457 
complicated the existing treatment modalities for tuberculosis, and there has been a recent increase 458 
in incidents of tuberculosis globally observed, the need for new effective, safe and affordable 459 
antimycobacterial drugs has become paramount. Calophyllum brasiliense extract was reported to be 460 
active against M. tuberculosis (IC50 3.02–3.64 𝜇g/mL), and a follow up HPLC analysis of the active 461 
extract provided evidence of presence of calanolides and the antimycobacterial activity induced by 462 
C. brasilliense was attributed mainly to calanolides A (1) and B (4) [62]. Earlier, Xu et al. [60] 463 
demonstrated that calanolide A (1), from Colombian C. lanigerum, was active against both drug-464 
susceptible and drug-resistant strains of Mycobacterium tuberculosis, e.g.,  H37Ra (ATCC 25177), 465 
H37Rv (ATCC 27294), CSU 19, CSU 33, H37Rv-INH-R (ATCC 35822), CSU 36, CSU 38 and H37Rv-466 
EMB-R (ATCC 35837). Efficacy evaluations in macrophages established that this pyranocoumarin 467 
could inhibit intracellular replication of M. tuberculosis at concentrations below the minimum 468 
inhibitory concentration (MIC) determined in vitro. It was postulated that calanolide A (1), like the 469 
antitubercular drug rifampicin, could rapidly inhibit RNA and DNA synthesis followed by an 470 
inhibition of protein synthesis, and could lead to the generation of a new class of pyranocoumarin-471 
based antitubercular drugs. In this study, the natural calanolides A (1), B (4) and D (7), as well as their 472 
semisynthetic analogues were tested, and (+)-calanolide A (1) and the semisynthetic analogue, 7,8-473 
dihydrocalanolide B emerged as most effective against tuberculosis with the MIC value of 3.13 474 
g/mL. While (-)-calanolide B (14) was moderately effective, calanolide D (7) was found inactive at 475 
the highest tested concentration of 12.5 g/mL. In fact, calanolides, especially calanolide A (1), is 476 
unique in a sense that these compounds have anti-HIV property and were found to be active against 477 
M. tuberculosis (MIC = 3.1 g/mL) and an array of drug-resistant strains (MIC = 8-16 g/mL). The 478 
antimycobacterial activity of calanolide A (1) is comparable to that of the well-known anti-tubercular 479 
drug isoniazid, and effective against rifampicin- and streptomycin-resistant M. tuberculosis strains. A 480 
recent patent described potent antimycobacterial property of calanolides and their analogs and 481 
provided a method of using these compounds for the treatment and prevention of mycobacterial 482 
infections [63]. 483 
4.4 Antiparasitic activity 484 
 Traditionally, natural products, especially in crude forms, have long been used to treat various 485 
parasitic diseases, like babesiosis, leishmaniasis, malaria, trypanosomiasis and so on. Recently, 486 
leishmaniasis and trypanosomiasis have been in research focus of natural products researchers, 487 
aiming at discovering new drug candidates to treat these neglected diseases [64, 65]. Extracts of C. 488 
brasiliense and C. inophyllum and calanolides were shown effective against intracellular parasites 489 
causing American trypanosomiasis and leishmaniasis [6]. In a recent study, Silva et al. (2020) [14] 490 
demonstrated that the MeOH extract from stem bark of C. brasiliense was active against amastigote 491 
forms of Trypanosoma cruzi and Leishmania infantum. Bioactivity-guided purification of the extra 492 
afforded calanolides E1 (11) and E2 (12), which were found to be active against T. cruzi (EC50 values 493 
of 12.1 and 8.2 M, respectively) and L. infantum, (EC50 values of 37.1 and 29.1 M, respectively) in 494 
vitro. Calanolide E1 (11) displayed the best selectivity index (SI) with values >24.4 to T. cruzi and >6.9 495 
to L. infantum in comparison to calanolide E2 (12). It was concluded that these coumarins could be 496 
utilized as scaffolds for the design and development of novel drug candidates to treat Leishmaniasis 497 
and Chagas diseases. 498 
 499 
 500 
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5. Toxicological aspects including pharmacokinetics 501 
Among the naturally occurring calanolides (Figure 2), calanolide A (1), a specific nonnucleoside 502 
inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, first isolated from 503 
a tropical tree C. lanigerum that grows abundantly in the Malaysian rain forest, is the most-studied 504 
compound in terms of its pharmacology, toxicology and synthesis. A series of animal studies [35] 505 
involving mice, rats and dogs established that calanolide A (1) is generally well-tolerated at oral doses 506 
of up to 150 mg/kg in rats and 100 mg/kg in dogs, and possesses a good safety profile [66, 67]. 507 
Calenolides A (1), B (4) and C (6) were found to be nontoxic in mice (LD50 = 1.99 g/kg), and no 508 
alternation on hepatocytes could be observed during the histological study of the mice treated with 509 
the highest dose applied [67]. During a study looking at the anti-HIV efficacy and toxicity of 510 
calanolides when used in combination with other anti-HIV drugs, no noticeable toxicity could be 511 
detected [38].  512 
In the very first study on the safety and pharmacokinetics of calanolide A (1) in healthy HIV-513 
negative human volunteers revealed that the toxicity of calanolide A (1) was minimal in the majority 514 
of subjects treated with four successive single dose, 200, 400, 600 and 800 mg. While there were no 515 
acute serious or life-threatening adverse effects were observed, among the usual minor adverse 516 
effects, dizziness, oily taste, headache, eructation, and nausea were noticed, but were of minimal 517 
clinical significance. These adverse effects were non-dose-dependent [66]. In this study, it was found 518 
that calanolide A (1) was rapidly absorbed following administration, with time to maximum 519 
concentration of drug in plasma (Tmax) values, depending on the doses, occurring between 2.4 and 5.2 520 
h. It was noted that the levels of calanolide A (1) in human plasma were higher than would have been 521 
predicted from animal studies, but the safety profile was benign. However, taking calanolide A (1) 522 
with food was found to generate significant variability in pharmacokinetics, but with no detectable 523 
interaction with food. Later, these findings were further confirmed by another similar study carried 524 
out by Eiznhamer et al. [68]. Calanolide A (1), the first member of the new family of NNRTIs, was 525 
found to have long elimination half-life, the benign toxicity profile, to achieve trough plasma levels 526 
approximating the EC90 of calanolide A (1) for HIV-1, to have the potential for twice daily dosing, 527 
and to offer the unique HIV-1 resistance profile could make this compound an attractive candidate 528 
for further clinical studies. It was reported that after oral administration, (+)-calanolide A (1) was 529 
generally well tolerated and indication of any safety concern could be observed [40]. Its plasma 530 
concentrations in humans were higher than anticipated from animal data. The AUC and Cmax values 531 
increased with increasing dose, and it appeared that therapeutic levels could easily be achieved in 532 
humans.  533 
A comparative study on the relative pharamacokinetic parameters and bioavailability of 534 
calanolide A (1) and its synthetic analogue dihydrocalanolide A (15) was reported [69]. This study 535 
compared the intravenous pharmacokinetics of the dihydro analog relative to the parent compound, 536 
calanolide A (1), and determined the relative oral bioavailability of each drug in CD2F1 mice. Both 537 
compounds displayed similar pharmacokinetic parameters, but the oral bioavailability of the dihydro 538 
analogue was considerably better (almost 3.5-fold) than calanolide A (1). Moreover, the relative 539 
ability of calanolide A (1) and its dihydro analog to change to their inactive epimer forms, (+)-540 
calanolide B (4) and (+)-dihydrocalanolide B, respectively, was also determined; while conversion of 541 
active calanolides to inactive forms occurred in vitro especially under acidic conditions, no epimers 542 
of either compound were observed in plasma of mice after administration of either (+)-calanolide A 543 
(1) or (+)-dihydrocalanolide A (15). It was suggested that the selection of the dihydro derivative of 544 
calanolide A (1) could be a reasonable choice for further preclinical development and possible Phase 545 
I clinical evaluation as an oral drug candidate for the treatment of HIV infection. Calanolide A (1) 546 
was shown to be distributed readily into the brain and lymph [47]. The distribution and elimination 547 
pattern of calanolide A (1) and its 7,8-dihydro derivative were found to be similar, but the apparent 548 
volume of distribution (Vd) and oral clearance of these compounds were significantly different after 549 
oral administration. It was also demonstrated that calanolide A (1) is generally well tolerated in doses 550 
up to 600 mg. As evident from animal studies, the gastrointestinal intolerance for this compound is 551 
not severe, but the most common adverse events as observed in human trails of calanolide A (1) 552 
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include an oily after taste and transient dizziness [47]. The calculated half-life of calanolide A (1) from 553 
800 mg dosing was reported to be 20 h [47, 66].  554 
During the study directed to the evaluation of antitubercular property of calanolides and their 555 
semisynthetic analogues, the pharmacokinetic data indicated that the (+)-calanolide A (1) 556 
concentrations in plasma could be comparable to the observed in vitro MICs against M. tuberculosis 557 
[60].  Both calanolides A (1) and B (4) metabolized by cytochrome P450 CYP3A, and their blood 558 
levels could be enhanced if co-administered with ritonavir. Usach et al. [70] reported the safety, 559 
tolerability and pharmacokinetics profiles of calanolide A (1), as a result of a comprehensive Phase I 560 
clinical trial. 561 
6. Therapeutic potential 562 
 Naturally occurring calanolides and their synthetic or semi-synthetic analogs have undergone 563 
several pre-clinical and clinical trials for their anti-HIV activity, aiming at novel anti-HIV drug 564 
development [2, 47, 71, 72]. In fact, calanolide A (1) was at an advanced stage of development as an 565 
anti-HIV drug about a decade ago (Singh et al., 2010) [72]. Buckheit [73] reviewed therapeutic 566 
potential of non-nucleoside reverse transcriptase inhibitors like calanolides as anti-HIV and 567 
commented on strategies for the treatment modalities for HIV infections. In fact, NNRTIs opened a 568 
new avenue of treatment of HIV infections, as previously this therapeutic area was predominantly 569 
covered by nucleoside reverse transcriptase inhibitors and protease inhibitors. Soon after the 570 
discovery of calanolides as a potential ant-HIV agents by the NCI/NIH, Sarawak Medichem 571 
Pharmaceuticals synthesized calanolide A (1) and started developing calanolide A (1) as a clinical 572 
drug for the treatment of HIV infections. It was a joint venture between the Sarawak State 573 
Government and Medichem Research Inc.  574 
During 2001-2005, an interventional clinical trial was conducted on human volunteers [74], 575 
where patients were randomized to receive (+)-calanolide A (1) or placebo for 21 days. All patients 576 
could elect to receive an open-label, 3-month course of approved retroviral therapy (up to triple-drug 577 
therapy) to be selected by, and administered under the care of, the patients' physicians. If the patient 578 
had no insurance coverage or did not wish to utilize his/her insurance for anti-HIV medications, 579 
Sarawak MediChem Pharmaceuticals provided these medications at no charge for up to three 580 
months. The trial was primarily aimed at the assessment of the safety and effectiveness of (+)-581 
calanolide A (1) in HIV-infected patients who had never taken anti-HIV drugs. In 2006, Craun 582 
Research, a company established by the Sarawak Government, acquired Sarawak MediChem, and in 583 
2016, Craun Research announced the completion of Phase I clinical trials for calanolide A (1) with 584 
doses of 200 to 800 mg, which initially started in 2013 [70]. In 2017, F18 (10-chloromethyl-11-585 
demethyl-12-oxo-calanolide A), a synthetic structural analog of calanolide A (1) was shown to have 586 
more potent anti-HIV activity than original molecule, calanolide A (1) [75, 76]. This compound 587 
showed better druggable profile with 32.7% oral bioavailability in rat, tolerable oral single-dose 588 
toxicity in mice, and suppressed both the wild type HIV-1 and Y181C mutant HIV-1 at an EC50 of 7.4 589 
nM and 0.46 nM, respectively [77]. Furthermore, it was shown that two enantiomers F18, (R)-F18 and 590 
(S)-F18, had quite similar anti-HIV property, but (R)-F18 was more potent than (S)-F18 against wild 591 
type virus, K101E mutation and P225H mutation pseudoviruses [75]. However, calanolides, 592 
particularly calanolide A (1) remains as an investigational anti-HIV drug and has not yet been 593 
approved by the FDA or any other drugs regulatory bodies for their commercial pharmaceutical 594 
production. 595 
7. Patents 596 
In 1999, calanolides and related antiviral compounds were patented by the Board of Trustees of 597 
the University of Illinois [78]. The patent covered novel antiviral compounds, calanolides, and their 598 
derivatives that could be isolated from plants of the genus Calophyllum in accordance with the 599 
specified method. The patent also included the uses of these compounds and their derivatives alone 600 
or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, 601 
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to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human 602 
immunodeficiency virus, specifically HIV-1 or HIV-2. Later, another patent, owned by Parker 603 
Hughes Institute, was reported, which described the novel uses of calanolides as Tec family/BTK 604 
(Bruton's tyrosine kinase) inhibitors, methods for their identification, and pharmaceutical 605 
compositions [79]. It can be mentioned here that the BTK inhibitors inhibit the enzyme BTK, which is 606 
a crucial part of the B-cell receptor signaling pathway, and these inhibitors have emerged as a new 607 
therapeutic target in a variety of malignancies, e.g. chronic lymphocytic leukemia and small 608 
lymphocytic lymphoma [80]. 609 
8. Conclusions 610 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz, nevirapine and 611 
delavirdine, have become one of the cornerstones of highly active anti-retroviral therapy for HIV 612 
infections. Calanolides, as they belong to this pharmacological class of NNRTIs, and because of their 613 
high safety margins and favorable pharmacokinetic profiles, are ideal candidates for novel anti-HIV 614 
drug development. While several analogues of the naturally occurring calanolides have been 615 
synthesized, a good number of preclinical and clinical trials have been conducted to date, and there 616 
are a few patents published, further work is still required to commercially bring any of the calanolide 617 
candidates, natural or synthetic, to anti-HIV drug market. As calanolides show an excellent 618 
synergistic and additive profile in combination with other anti-HIV drugs, it is assumed that 619 
calanolides can be considered for use in combination therapy for HIV infections. 620 
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